Umbrella Labs announced Monday May 25 a documentation and traceability update for its Epitalon peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's standardization initiative focused on identity-field consistency, record continuity, and reproducibility — the same template Umbrella applied to Dihexa on May 19. Epitalon (Glu-Asp-Gly-Lys) is a four-amino-acid peptide originally derived from the bovine pineal gland by Vladimir Khavinson and studied as a senescent-cell modulator and telomerase activator. The peptide is on the FDA's PCAC review docket for July 23-24, 2026 — Day 2 alongside Emideltide/DSIP and Semax — for potential 503A bulks-list inclusion. Reference-material standardization across the research-peptide supply chain is the soft regulatory signal that compounding pharmacies and supply networks are preparing for the PCAC review window.
Umbrella Labs announced Tuesday May 19 a documentation and traceability update for its dihexa peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's ongoing standardization initiative focused on identity-field consistency, record continuity, and reproducibility support for research laboratories. The timing aligns with the FDA-confirmed February 2027 PCAC meeting that will review dihexa acetate for potential 503A bulks-list inclusion alongside GHK-Cu, Melanotan II, LL-37, and PEG-MGF. Dihexa is a small angiotensin IV-derived peptide originally studied at Washington State University for hepatocyte growth factor activation and neuroprotection. Reference-material traceability standards are a soft signal of the regulatory cycle compounding pharmacies and supply chains are preparing for ahead of the PCAC review.
UK-based BSR — Biotech Scientific Research — published a peptide industry briefing covering March through early-May 2026 with concrete supply-chain and quality-control data points. Compounded semaglutide shipment volumes are down 90% year-over-year and tirzepatide down 34% as the FDA-declared shortage resolution shifts demand back to branded supply; the April 30 proposal to exclude both drugs from the 503B bulks list continues to compress the compounded segment with comments closing June 29. On the quality side, the briefing cites the 2018 falsification analysis showing research-peptide purity ranging from 5% to 75% with lead concentrations 10x safety limits, plus current evidence of fake Certificates of Analysis from Chinese-sourced products that don't match actual contents. The 'CORE PEPTIDES' scam was flagged January 2026 with documented $500 losses via Cash App and no recourse. 455+ FDA adverse-event reports for compounded semaglutide alone trace back to dosing errors from patients self-administering incorrect doses from multidose vials.